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Background: Superficial venous disease, which includes superficial venous thrombosis (SVT) and varicose veins, may be associated with a
higher risk of venous thromboembolism (VTE). Use of combined hormonal contraceptives (CHCs) has been associated with an increased risk
of VTE compared with nonuse. Little is known about whether use of CHCs by women with superficial venous disease may further elevate the
risk of VTE.
Objectives: To investigate evidence regarding risk of VTE in women with SVT or varicose veins who use CHCs compared with non-CHC users.
Methods: We searched the PubMed database for all English-language articles published from database inception through September 2014.
We included primary research studies that examined women with SVT or varicose veins who used CHCs compared to women with these
conditions who did not use CHCs. Outcomes of interest included VTE (among women with SVT or varicose veins) and SVT (for those with
varicose veins).
Results: Two studies were identified that met inclusion criteria. One fair-quality case–control study reported an odds ratio (OR) for VTE of 43.0
(95% confidence interval [CI] 15.5–119.3) among women with SVT using oral contraceptives (OCs) compared with nonusers without SVT. The
OR for VTE was also increased for women with SVT not using OCs (OR 5.1; 95% CI 2.8–9.5) and for women without SVT using OCs (OR 4.0;
95% CI 3.3–4.7), compared with nonusers without SVT. One fair-quality cohort study demonstrated that women with varicose veins had an
increased rate of VTE with use of OCs (1.85 per 1000 women-years [WY]), compared with users without varicose veins (0.84 per 1000 WY),
nonusers with varicose veins (0.31 per 1000 WY) and nonusers without varicose veins (0.19 per 1000 WY). This study also demonstrated that
womenwith varicose veins had an increased rate of SVTwith use of OCs (10.63 per 1000WY), compared with nonusers with varicose veins (7.59
per 1000 WY), users without varicose veins (1.89 per 1000 WY) and nonusers without varicose veins (0.77 per 1000 WY).
Conclusion: Two studies suggest increased risk of VTE among OC users with superficial venous disease; however, no definitive conclusions
can be made due to the limited number of studies and limitations in study quality. Theoretical concerns need to be clarified with further
research on whether the risk of significant sequelae from superficial venous disease among CHC users is related to clinical severity of disease
and underlying factors.
© 2016 Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Superficial venous disease; Superficial venous thrombosis; Varicose veins; Oral contraceptives; Systematic review1. Introduction
Superficial venous disease includes varicose veins and
superficial venous thrombosis (SVT) [1]. The prevalence of☆ Disclaimer: The findings and conclusions in this report are those of
the authors and do not necessarily represent the official position of the US
Centers for Disease Control and Prevention.
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http://dx.doi.org/10.1016/j.contraception.2015.03.010
0010-7824/© 2016 Published by Elsevier Inc. This is an open access article under the Cvaricose veins among women ranges widely in published
literature from less than 1% to 73%, with more recent studies
demonstrating prevalences of approximately 30% [2]. The
incidence of SVT is not well studied, but the preponderance
(60%–80% of cases) occurs in women [3–5]. Although once
thought to be fairly benign, SVT has increasingly been found
to be associated with venous thromboembolism (VTE),
including deep venous thrombosis (DVT) and pulmonary
embolism (PE) [1]. Use of combined hormonal contracep-
tives (CHCs) increases the risk of VTE in healthy women
compared with nonusers [6]. Given that SVT and CHCs may
be independent risk factors for VTE, there is theoreticalC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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elevate the risk of VTE.
The World Health Organization's (WHO) Medical
Eligibility Criteria for Contraceptive Use (MEC) currently
recommends that women with varicose veins can use CHCs
(MEC Category 1) and women with superficial thrombo-
phlebitis generally can use CHCs (MEC Category 2) [7].
This systematic review was conducted as part of the process
of updating the MEC. We sought evidence regarding
whether CHCs increase the risk of VTE in women with
superficial venous disease. Our specific question was
whether women with superficial venous disease who use
CHCs have a higher risk of VTE than women with
superficial venous disease who do not use CHCs.2. Materials and methods
We conducted this systematic review according to
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) guidelines [8].
2.1. Literature search
We searched the PubMed database for all relevant articles
published from database inception through September 2014
using the following search strategies:
Search strategy for SVT:
((“Thrombophlebitis”[Mesh] OR superficial thrombo-
phlebitis OR superficial vein thrombosis OR superficial
venous thrombosis)) AND (((((((((“Contraceptives,
Oral”[Mesh]) OR “oral contraceptives”)) OR oral contra-
cept*))) OR (“Ortho Evra”[Supplementary Concept] OR
ortho evra OR “contraceptive patch” OR “transdermal
patch”)) OR (“NuvaRing”[Supplementary Concept] OR
nuvaring OR “vaginal ring”)) OR (((once a month OR
monthly) AND inject*) AND contracept* OR cyclofem
OR lunelle OR mesigyna OR cycloprovera))
Search strategy for varicose veins:
((“Varicose Veins”[Mesh] OR varicose vein* OR var-
icosit*)) AND ((((((((((“Contraceptives, Oral”[Mesh])
OR “oral contraceptives”)) OR oral contracept*))) OR
(“Ortho Evra”[Supplementary Concept] OR ortho evra
OR “contraceptive patch” OR “transdermal patch”)) OR
(“NuvaRing”[Supplementary Concept] OR nuvaring OR
“vaginal ring”)) OR (((once a month OR monthly) AND
inject*) AND contracept* OR cyclofem OR lunelle OR
mesigyna OR cycloprovera)) AND Humans[Mesh])
We searched for all primary research articles published in
any language. We excluded articles published in non-English
languages that did not have an English abstract. We also
searched reference lists of identified articles and relevant
review articles for additional citations of interest. We did not
consider unpublished studies, abstracts of conference
presentations or dissertations.2.2. Selection criteria
Articles were included in this review if they were primary
reports on studies examining women with SVT or varicose
veins using CHCs (pills, patches, rings and injectables
containing both ethinyl estradiol and a progestin). Outcomes
of interest among women with SVT included venous
thromboembolic complications, including DVT and PE.
Outcomes of interest among women with varicose veins
included VTE and SVT. We included studies that examined
women using unspecified formulations of oral contraceptives
(OCs); while some of these women may have been using
progestin-only formulations, we assume that the great majority
of women would have been using combined formulations.
2.3. Study quality assessment and data synthesis
Two authors (N.T. and K.C.) summarized and systemat-
ically assessed the evidence. We assessed the quality of each
individual piece of evidence using the system developed by
the United States Preventive Services Task Force (USPSTF)
[9,10]. Summary measures were not calculated.3. Results
3.1. Women with SVT
The search identified 572 articles, of which one article
met the criteria for inclusion (Table 1) [11]. The remaining
articles were excluded because they addressed DVT but not
SVT, were review articles, or otherwise did not address the
question of interest. The included study examined the risk of
VTE in women with SVT using OCs (not further specified).
The analysis was a substudy of the Multiple Environmental
and Genetic Assessment (MEGA) study, a large case–
control study examining risk factors for VTE conducted in
the Netherlands. For this analysis, cases were premenopausal
women aged 18–50 years with a first episode of VTE
recruited from anticoagulation clinics. Partner controls were
female partners of male VTE cases; these controls were also
aged 18–50 years with no history of VTE. Community
controls were recruited by random digit dialing and matched
by age and sex. Information on OC use in the month before
and SVT at any time before VTE (cases) or before interview
(controls) was obtained by participant questionnaires. DVT
and PE diagnoses were obtained by review of hospital
discharge reports and general practitioner records, including
confirmatory radiologic studies. Odds ratios (ORs) for VTE
were highest in women with a history of SVT who used OCs,
compared with non-OC users with no history of SVT.
Among women with SVT using OCs, OR for VTE was 43.0
(95% confidence interval [CI] 15.5–119.3) compared with
nonusers without SVT. The OR for VTE was also increased
for women with SVT not using OCs (OR 5.1; 95% CI 2.8–
9.5) and for women without SVT using OCs (OR 4.0; 95%
CI 3.3–4.7), compared with nonusers without SVT. Similar
trends were seen for DVT alone, PE alone and DVT with
Table 1
Evidence for risk of VTE in users of CHCs who have superficial venous disease.
Author,
year, location, 
support
Study 
Design
Population Contraceptive Results Strengths Weaknesses Quality 
Grading 
RCGP [12], 
1978
United 
Kingdom
Medical 
Research 
Council, Royal 
College of 
General 
Practitioners, 
Organon 
Laboratories 
Ltd, Ortho 
Pharmaceutical 
Corp, Schering 
Chemicals Ltd, 
G.D. Searle and 
Co. Ltd, Syntex 
Pharmaceuticals 
Ltd, and John 
Wyeth and 
Brother Ltd
Prospective 
cohort
OC users: 
Women 
currently using 
OCs recruited 
from general 
practitioners
Controls: Non–
users matched 
for age and 
marital status
OCs (not 
further 
specified)
Risk of DVT:
Varicose 
veins
Users
(N)
Users
(Rate/1000 
WY)
Non–
users
(N)
Non–users
(Rate/1000 
WY)
Rate 
ratio*
Yes 9 1.85 3 0.31 5.97
No 30 0.84 9 0.19 4.42
Rate 
ratio
2.20 
(p<0.05)
1.66 (NS)
* Calculated by review authors
Risk of SVT:
Varicose 
veins
Users
(N)
Users
(Rate/1000 
WY)
Non–
users
(N)
Non–users
(Rate/1000 
WY)
Rate 
ratio*
Yes 54 10.63 72 7.59 1.40
No 67 1.89 36 0.77 2.45
Rate
ratio
5.62
(p<0.005)
9.87
(p<0.005)
* Calculated by review authors
Excluded 
women with 
certain risks 
for VTE
Rates 
standardized 
for age, 
parity, 
smoking, 
and social 
class
Varicose 
veins, SVT 
and VTE 
diagnoses 
from general 
practitioners, 
not verified 
by review of 
radiologic 
studies
No 
information 
on OC type
OC use 
reported by 
general 
practitioners 
without 
additional 
verification
Small 
numbers for 
comparisons 
of interest
II–2, 
fair
Roach [11], 
2013
Netherlands
Case–
control
Women ages 
18–50
Cases: from 
anticoagulation 
clinic with first 
DVT or PE
OCs (not 
further 
specified)
Odds of VTE:
SVT
history
OC 
use
Cases
(N)
Controls
(N)
VTE
aOR* (95% CI)
VTE 
confirmed 
by 
radiology 
results from 
hospital 
discharge 
and general 
practitioners
Information 
on SVT 
obtained via 
questionnaire, 
not 
objectively 
verified
II–2, 
fair
Netherlands 
Heart 
Foundation, 
Dutch Cancer 
Foundation, 
Netherlands 
Organization 
for Scientific 
Research
Partner 
controls: 
partners of 
male patients 
Community 
controls: 
random digit 
dialing, age 
and sex 
matched
Use in month 
before VTE
(cases) or 
interview 
(control)
Negative No 416 1046 Ref
Negative Yes 902 642 4.0 (3.3–4.7)
Positive No 41 18 5.1 (2.8–9.5)
Positive Yes 86 5 43.0 (15.5–119.3)
SVT history OC use DVT
aOR* (95% CI)
Negative No Ref
Negative Yes 4.4 (3.6–5.4)
Positive No 5.1 (2.5–10.5)
Positive Yes 46.8 (16.5–133.0)
SVT history OC use DVT withPE
aOR* (95% CI)
Negative No Ref
Negative Yes 7.1 (4.1–12.5)
Positive No 12.5 (3.6–43.3)
Positive Yes 100.4 (24.2–416.0)
SVT history OC use PE
aOR* (95% CI)
Negative No Ref
Negative Yes 3.5 (2.7–4.5)
Positive No 4.3 (1.9–10.0)
Positive Yes 33.2 (10.9–101.5)
* aOR adjusted for age, BMI, smoking, family history 
VTE.
Information 
on OC use 
obtained via 
questionnaire
No 
information 
on timing, 
location or 
severity of 
SVT
No 
information 
on OC type
Small 
numbers and 
wide 
confidence 
intervals for 
some OR
Abbreviations: aOR, adjusted OR; BMI, body mass index; NS, not significant; RCGP, Royal College of General Practitioners.
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of VTE (calculated for purposes of this review) was 8.4
among OC users compared with nonusers.
3.2. Women with varicose veins
The search identified 108 articles, of which one article
met the criteria for inclusion (Table 1) [12]. The remainingarticles were excluded because they addressed the develop-
ment of varicose veins in healthy women, were review
articles, or otherwise did not address the question of interest.
The included study examined the risk of DVT or SVT in
women with varicose veins using OCs (not further
specified). The analysis used data from the Royal College
of General Practitioners' (RCGP) Oral Contraception Study,
278 N.K. Tepper et al. / Contraception 94 (2016) 275–279a prospective cohort study of OC users. Women using OCs
were recruited from many general practices in the United
Kingdom. Women not using OCs and matched for age and
marital status were recruited from the same general practices.
Information on varicose veins, SVT and DVT was obtained
by report from the general practitioners, without medical
record review by study authors (personal communication
with study authors). Information on OC use was reported by
the general practitioners [13]. The rate of DVT or SVT was
highest among women with varicose veins who used OCs.
For the outcome of DVT, among women with varicose veins
without other thrombotic risk factors, the rate of DVT was
1.85 per 1000 women-years (WY) in OC users and 0.31 per
1000 WY in nonusers, for a rate ratio of 5.97 (calculated for
purposes of this review). Among women without varicose
veins, the rate of DVT was 0.84 per 1000 WY in OC users
and 0.19 per 1000 WY in nonusers, for a rate ratio of 4.42
(calculated for purposes of this review). For the outcome of
SVT, among women with varicose veins, the rate of SVT
was 10.63 per 1000 WY in OC users and 7.59 per 1000 WY
in nonusers, for a rate ratio of 1.40 (calculated for purposes
of this review). Among women without varicose veins, the
rate of SVT was 1.89 per 1000 WY in OC users and 0.77 per
1000 WY in nonusers, for a rate ratio of 2.45 (calculated for
purposes of this review).4. Discussion
This systematic review identified minimal evidence on
VTE risk in women with superficial venous disease who
used CHCs compared with nonusers. One fair-quality case–
control study demonstrated that women with SVT had an
increased odds of VTE with use of OCs [11]. In decreasing
order of magnitude, the odds of VTE was elevated in OC
users with SVT, nonusers with SVT and users without SVT,
compared with nonusers without SVT, although CIs were
sometimes wide and overlapping. While the point estimates
suggest an interaction between SVT and CHC use on the risk
of VTE, no formal testing for statistical interaction was
reported. One fair-quality cohort study demonstrated that
women with varicose veins had an increased rate of VTE
with use of OCs [12]. In decreasing order of magnitude, the
rate of VTE was highest in OC users with varicose veins,
users without varicose veins and nonusers with varicose
veins, compared with nonusers without varicose veins. This
study also demonstrated an increased rate of SVT in women
with varicose veins using OCs.
Both studies provided USPSTF Level II-2 evidence
because they were cohort studies. Both studies were rated as
fair quality, because they demonstrated strengths in study
design, and although both had limitations, there were no fatal
flaws. Neither study specified OC type or estrogen dose. It is
likely that the OCs used were predominantly combined OCs.
While the RCGP study reported few users of OCs with
N50 mcg estrogen and the MEGA study likely also had fewhigh-dose users given timing of data collection (1999–
2004), neither study examined different estrogen doses for
OCs containing b50 mcg. It is possible that any potential
relationship between superficial venous disease and VTE
would be attenuated by the progressively decreasing
estrogen levels in modern COCs. Both studies had small
numbers for comparisons of interest. In the MEGA study,
information on OC use and SVT history was obtained by
self-reported questionnaire and thus may be subject to recall
bias. The MEGA study also did not collect information on
timing, location or severity of SVT. In the RCGP study,
information on varicose veins, SVT and VTE was obtained
from the general practitioners but not verified by review of
medical records or radiologic studies; information on OC use
was also reported by general practitioners with no other
source of verification.
In considering the potential impact of CHC use by women
with SVT or varicose veins, it is important to take into
account the separate influences of CHC use and superficial
venous disease. Studies have demonstrated that healthy
women using CHCs have an incidence of VTE of
approximately 9–10 per 10,000 WY [14]. This risk is
increased compared with nonusers, by approximately 2- to
3-fold [6].
Several studies have reported increased risks of VTE in
individuals with SVT, with varying degrees of magnitude.
Some studies found that risk of VTE was 4- to 7-fold higher
in individuals with SVT; however, most of these studies did
not separately report these risks by gender and age
[11,15–17]. The frequency of concurrent DVT in individuals
with SVT varies from 6% to 53%, and concurrent PE varies
from 0.5% to 10% for symptomatic cases and up to 33%
diagnosed on lung scans [4,5,18–20]. Although results have
been inconsistent, some studies have found that the risk of
VTE was approximately 4- to 6-fold higher in individuals
with varicose veins [15,21]. It is likely that the risk of
significant sequelae from superficial venous disease is
related to clinical severity and underlying risk factors, such
as thrombophilias [1,4,5,22]. In individuals with SVT,
concurrent DVT most often is found in the same limb as
the SVT, but in a small number of cases (2%), the DVT
develops in the opposite limb, suggesting that the association
may be due either to progression of the clot or to a
hypercoagulable state [5]. Absence of varicose veins has
been associated with concurrent DVT in patients with SVT
[20]. Nonetheless, additional studies are needed in order to
better understand the predictors of development of DVT in
patients with superficial venous disease and to explore how
hormones might interact with these thrombotic mechanisms.
In summary, minimal evidence from two observational
studies of fair quality was identified regarding the risk of
VTE in women with superficial venous disease who use
CHCs. One case–control study demonstrated a higher risk of
VTE in women with SVT who used OCs, and one cohort
study demonstrated a higher rate of VTE in women with
varicose veins who used OCs. No evidence on other CHCs
279N.K. Tepper et al. / Contraception 94 (2016) 275–279was identified. Future studies should examine the risk of
VTE among women of reproductive age with varying
degrees of superficial venous disease and the possible
interaction with CHCs; if there are significant sequelae from
superficial venous disease among CHC users, it may be
related primarily to clinical severity of disease and other
underlying factors. The information in this review was
presented to an expert review panel in March 2014 at a
meeting convened by WHO. The findings of this systematic
review will be incorporated into the forthcoming update of
the WHO MEC.Acknowledgments
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